drugset
drugset / Trial / NCT03719131

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131 ↗

Phase 2 Completed 15 enrolled Emory University Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy.

Timeline

Start
2019-06-05
Primary completion
2022-09-27
Completion
2025-04-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab and Hyaluronidase Human Unknown — Intravenous
Background Ipilimumab Monoclonal antibody — —
Background Nivolumab Monoclonal antibody — —

Indications

cutaneous melanoma